Literature DB >> 27349725

Treatment of pulmonary exacerbations in cystic fibrosis - could do better?

Alan Smyth1.   

Abstract

This article describes the nature and significance of pulmonary exacerbations in cystic fibrosis (CF). The effectiveness and safety of current exacerbation treatment are explored. The article concludes with a summary of clinical trials (completed and ongoing) which aim to improve the efficacy and safety of exacerbation treatment.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adverse effects of antibiotics; Cystic fibrosis; Microbiome; Pulmonary exacerbations; Symptom score

Mesh：

Substances：

Year:  2016        PMID： 27349725     DOI： 10.1016/j.prrv.2016.06.004

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN： 1526-0542            Impact factor:   2.726


  3 in total

1.  Altered Stool Microbiota of Infants with Cystic Fibrosis Shows a Reduction in Genera Associated with Immune Programming from Birth.

Authors:  Katherine M Antosca; Diana A Chernikova; Courtney E Price; Kathryn L Ruoff; Kewei Li; Margaret F Guill; Natalie R Sontag; Hilary G Morrison; Shuyu Hao; Mitchell L Drumm; Todd A MacKenzie; Dana B Dorman; Lynn M Feenan; Molly A Williams; John Dessaint; Irene H Yuan; Brian J Aldrich; Lisa A Moulton; Lily Ting; Ana Martinez-Del Campo; Edward J Stewart; Margaret R Karagas; George A O'Toole; Juliette C Madan
Journal:  J Bacteriol       Date:  2019-07-24       Impact factor: 3.490

Review 2.  Cystic Fibrosis Airway Microbiome: Overturning the Old, Opening the Way for the New.

Authors:  George A O'Toole
Journal:  J Bacteriol       Date:  2018-01-24       Impact factor: 3.490

3.  Outcomes and Safety of Outpatient Parenteral Antimicrobial Therapy in Select Children with Cystic Fibrosis.

Authors:  Gulnur Com; Amit Agarwal; Shasha Bai; Zhuopei Hu; Grace Goode; Hollyn McCarty; Ariel Berlinski
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-12-11       Impact factor: 1.349
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.